Suppressor PAQR3 associated with the clinical significance and prognosis in esophageal squamous cell carcinoma

Bai,Ge; Yang,Mei; Zheng,Chao; Zhang,Li; Eli,Mayinur

doi:10.3892/ol.2018.8004

Suppressor PAQR3 associated with the clinical significance and prognosis in esophageal squamous cell carcinoma

Authors:
- Ge Bai
- Mei Yang
- Chao Zheng
- Li Zhang
- Mayinur Eli
View Affiliations

Affiliations: Cancer Center, The First Affiliated Hospital of Xinjiang Medical University, Ürümqi, Xinjiang Uyghur Autonomous Region 830011, P.R. China, VIP Medicine, The First Affiliated Hospital of Xinjiang Medical University, Ürümqi, Xinjiang Uyghur Autonomous Region 830011, P.R. China
Published online on: February 8, 2018 https://doi.org/10.3892/ol.2018.8004
Pages: 5703-5711
Copyright: © Bai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Progestin and adipoQ receptor family member 3 (PAQR3) is a novel tumor suppressor; however, its function in esophageal cancer is not well understood. The present study explored the association between PAQR3, and the survival and clinical phenotype in patients with esophageal squamous cell carcinoma (ESCC). The expression of PAQR3 in 80 cases of ESCC and its corresponding adjacent tissues was detected by reverse transcription‑quantitative polymerase chain reaction. The results demonstrated that PAQR3 expression in cancer tissues was significantly lower compared with that in adjacent tissues. Clinicopathological analysis indicated that PAQR3 expression was significantly correlated with ethnicity (P=0.032), tumor length (P=0.019), lymph node metastasis (P=0.011) and local recurrence (P=0.009). Notably, the Kaplan‑Meier survival curve demonstrated that a decrease in PAQR3 expression was associated with poor prognosis in patients with ESCC. Multivariate analysis indicated that PAQR3 expression was an independent prognostic indicator for patients with ESCC. PAQR3 may serve an important role in the progress of ESCC and become a potential candidate for ESCC targeted therapy.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
3	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
4	Samatar AA and Poulikakos PI: Targeting RAS-ERK signalling in cancer: Promises and challenges. Nat Rev Drug Discov. 13:928–942. 2014. View Article : Google Scholar : PubMed/NCBI
5	Tasioudi KE, Saetta AA, Sakellariou S, Levidou G, Michalopoulos NV, Theodorou D, Patsouris E and Korkolopoulou P: pERK activation in esophageal carcinomas: Clinicopathological associations. Pathol Res Pract. 208:398–404. 2012. View Article : Google Scholar : PubMed/NCBI
6	Feng L, Xie X, Ding Q, Luo X, He J, Fan F, Liu W, Wang Z and Chen Y: Spatial regulation of Raf kinase signaling by PAQR3. Proc Natl Acad Sci USA. 104:pp. 14348–14353. 2007; View Article : Google Scholar : PubMed/NCBI
7	Yu X, Li Z, Chan MT and Wu WK: PAQR3: A novel tumor suppressor gene. Am J Cancer Res. 5:2562–2568. 2015.PubMed/NCBI
8	Fan F, Feng L, He J, Wang X, Jiang X, Zhang Y, Wang Z and Chen Y: PAQR3 sequesters B-Raf to the Golgi apparatus and inhibits the proliferation and tumorigenicity of human malignant melanoma cells. Carcinogenesis. 29:1157–1163. 2008. View Article : Google Scholar : PubMed/NCBI
9	Xie X, Zhang Y, Jiang Y, Liu W, Ma H, Wang Z and Chen Y: Suppressive function of PAQR3 on chemical carcinogen-induced skin carcinogenesis in mouse. Carcinogenesis. 29:1632–1638. 2008. View Article : Google Scholar : PubMed/NCBI
10	Wu HG, Zhang WJ, Ding Q, Peng G, Zou ZW, Liu T, Cao RB, Fei SJ, Li PC, Yang KY, et al: Identification of PAQR3 as a new candidate tumor suppressor in hepatocellular carcinoma. Oncol Rep. 32:2687–2695. 2014. View Article : Google Scholar : PubMed/NCBI
11	Li Z, Ling ZQ, Guo W, Lu XX, Pan Y, Wang Z and Chen Y: PAQR3 expression is downregulated in human breast cancers and correlated with HER2 expression. Oncotarget. 6:12357–12368. 2015.PubMed/NCBI
12	Wang L, Wang X, Li Z, Xia T, Zhu L, Liu B, Zhang Y, Xiao F, Pan Y, Liu Y, et al: PAQR3 has modulatory roles in obesity, energy metabolism, and leptin signaling. Endocrinology. 154:4525–4535. 2013. View Article : Google Scholar : PubMed/NCBI
13	Qiao S, Guo W, Liao L, Wang L, Wang Z, Zhang R, Xu D, Zhang Y, Pan Y, Wang Z and Chen Y: DDB2 is involved in ubiquitination and degradation of PAQR3 and regulates tumorigenesis of gastric cancer cells. Biochem J. 469:469–480. 2015. View Article : Google Scholar : PubMed/NCBI
14	Ling ZQ, Guo W, Lu XX, Zhu X, Hong LL, Wang Z, Wang Z and Chen Y: A Golgi-specific protein PAQR3 is closely associated with the progression, metastasis and prognosis of human gastric cancers. Ann Oncol. 25:1363–1372. 2014. View Article : Google Scholar : PubMed/NCBI
15	Wang X, Li X, Fan F, Jiao S, Wang L, Zhu L, Pan Y, Wu G, Ling ZQ, Fang J and Chen Y: PAQR3 plays a suppressive role in the tumorigenesis of colorectal cancers. Carcinogenesis. 33:2228–2235. 2012. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Guo W, You X, Xu D, Zhang Y, Wang Z, Man K, Wang Z and Chen Y: PAQR3 enhances Twist1 degradation to suppress epithelial-mesenchymal transition and metastasis of gastric cancer cells. Carcinogenesis. 37:397–407. 2016. View Article : Google Scholar : PubMed/NCBI
18	Oncomine database. https://www.oncomine.org/resource/login.html
19	Zhang Y: Xinjiang esophageal cancer distribution. Xinjiang Medical College. 11:139–144. 1988.
20	Wang L, Pan Y, Huang M, You X, Guo F and Chen Y: PAQR3 augments amino acid deprivation-induced autophagy by inhibiting mTORC1 signaling. Cell Signal. 33:98–106. 2017. View Article : Google Scholar : PubMed/NCBI
21	Bai G, Chu J, Eli M, Bao Y and Wen H: PAQR3 overexpression suppresses the aggressive phenotype of esophageal squamous cell carcinoma cells through the ERK pathway. Biomed Pharmacother. 94:1–819. 2017. View Article : Google Scholar : PubMed/NCBI
22	Wu Q, Zhuang K and Li H: PAQR3 plays a suppressive role in laryngeal squamous cell carcinoma. Tumour Biol. 37:561–565. 2016. View Article : Google Scholar : PubMed/NCBI
23	Huang W, Guo W, You X, Pan Y, Dong Z, Jia G, Yang C and Chen Y: PAQR3 suppresses the proliferation, migration and tumorigenicity of human prostate cancer cells. Oncotarget. 8:53948–53958. 2016.PubMed/NCBI
24	Huang J, Xiang T, Luo X, Huang J, Xiao Y, Yang B, Yin X, Li H, Xia Li X, Peng W, et al: RKTG, a RAS/RAF/ERK signaling antagonist regulated by HER2, suppresses malignant phenotypes and enhances chemosensitivity in breast cancer cells. J Third Military Med Univ. 8:1658–1662. 2013.